CorMedix (CRMD) Tops Q2 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AAPL
2. AMD
3. PLTR
4. DOX
5. VRTX
6. CRWD
7. CHKP
8. ON
9. HNGE
10. INSP

Go back to CorMedix (CRMD) Tops Q2 EPS by 2c

CorMedix Inc. Reports Second Quarter and Six Month 2022 Financial Results and Provides Business Update

August 11, 2022 7:30 AM EDT

BERKELEY HEIGHTS, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for the second quarter and six months ended June 30, 2022 and provided an update on recent business events.

Recent Corporate Highlights:

CorMedix announced on August 8th that a second Complete Response Letter (CRL) was received from the FDA stating that the DefenCath NDA cannot be approved until... More